3 New Strong Buy Ratings from Top-Rated Analysts: 08/04/2026

Wall Street is salivating over these fundamentally sound tickers…

• Workiva (WK): Compliance software leader launches AI agents for growth
• TFI International (TFII): #1 trucking stock with awesome fundamentals
• Insulet (PODD): Diabetes tech leader with up to 118% upside potential

P.S. Get more alerts like this daily … Try WallStreetZen Premium.

A note from our sponsors...

1. Workiva (NYSE: WK)

With the recent launch of specialized AI agents and an intelligence layer, this cloud-based compliance company is advancing its platform capabilities and positioning itself for accelerated growth in the enterprise software space.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $59.80 — get current quote

Max 1-year forecast: $90.00

Why we're watching:

• WK has solid coverage among the analysts we track, with 4 Strong Buy and 1 Buy recommendations. See all recommendations here
• For example, Stifel Nicolaus researcher Brad Reback (a top 12% rated analyst) maintained his Strong Buy recommendation; Stephens & Co. researcher Brett Huff (a top 22% rated analyst) reiterated his Strong Buy with a price target suggesting the stock could see double-digit upside in the coming year. 
• Industry ranking context: WK is currently the #9 highest-rated stock in the App industry, which has an Industry Rating of B.
• Zen Ratings highlights: WK earns an overall A rating, which amounts to a Strong Buy recommendation. Stocks with this rating represent the elite top 5% of all stocks tracked based on a rigorous 115-factor fundamental review.
• Component Grades: WK excels with an A for Growth, reflecting the company's strong expansion trajectory and robust revenue forecasts, while maintaining solid Bs for Financials and Sentiment, a combination that positions it well for continued appreciation. See all 7 Component Grades here

2. TFI International (NYSE: TFII)

This transportation and logistics company has recently captured analyst attention following a strong Q2 performance that beat estimates and demonstrated operational momentum in a challenging freight environment.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $135.02 — get current quote

Max 1-year forecast: $205.00

Why we're watching:

• TFII has strong, bullish coverage among the analysts we track, with 7 Strong Buy, 2 Buy, and 3 Hold recommendations. See all recommendations here
• For example, Citigroup researcher Ariel Rosa (a top 3% rated analyst) maintained his Strong Buy rating with a price target that suggests the stock could see more than 30% upside in the coming year.  
• Six additional top-rated analysts covering TFII include Stephens & Co.'s Bascome Majors, Bank of America's Ken Hoexter, TD Cowen's Jason Seidl, RBC Capital's Walter Spracklin, JP Morgan's Brian Ossenbeck, and Stifel Nicolaus's J. Bruce Chan — all maintaining bullish outlooks on the trucking sector's recovery.
• Industry ranking context: TFII is currently the #1 highest-rated stock in the Trucking industry, which has an Industry Rating of A.
• Zen Ratings highlights: TFII earns an overall A rating, which is equal to a Strong Buy recommendation. Stocks in this topmost tier have historically delivered nearly 30% annual returns, soundly beating the S&P.
• Component Grades: TFII excels with As for Momentum and Sentiment, reflecting powerful price action and enthusiastic analyst support, while maintaining strong Bs for Growth, Financials, and Safety, a balanced mix that supports both near-term momentum and long-term fundamentals. See all 7 Component Grades here

3. Insulet (NASDAQ: PODD)

Despite recent legal headlines, this insulin-focused medical company's innovative product pipeline and strong market position in diabetes care continue to attract analyst interest and support its long-term growth trajectory.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $165.35 — get current quote

Max 1-year forecast: $360.00

Why we're watching:

• PODD has broad, bullish coverage among the analysts we track, with 9 Strong Buy, 5 Buy, 3 Hold, and 1 Strong Sell recommendations. See all recommendations here
• For example, Leerink Partners researcher Mike Kratky (a top 16% rated analyst) maintained his Buy rating with a price target implying greater than 115% upside potential in the coming year.
• More modest but still quite optimistic, Truist Securities researcher Richard Newitter (a top 13% rated analyst) maintained his Strong Buy with a price target suggesting the stock could see greater than 25% upside in the coming year. 
• Industry ranking context: PODD is currently the #9 highest-rated stock in the Medical Device industry, which has an Industry Rating of C.
• Zen Ratings highlights: PODD earns an overall A rating, equal to a Strong Buy recommendation. This tier represents the top 5% of stocks tracked based on a careful 115-factor fundamental analysis.
• Component Grades: PODD stands out with an A for Financials, reflecting the company's robust profitability and cash flow generation, while maintaining solid Bs for Growth and Value, a combination that supports both expansion potential and reasonable valuation levels. See all 7 Component Grades here

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.